TIM-3 Protein, Human, Recombinant (His & Fc Tag)

1/1
Price:
Size:
Number:

TIM-3 Protein, Human, Recombinant (His & Fc Tag): Product Information

Purity
> 88 % as determined by SDS-PAGE
Endotoxin
< 1.0 EU per μg of the protein as determined by the LAL method
Activity
Testing in progress
Protein Construction
A DNA sequence encoding the human TIMD3 (NP_116171.3) extracellular domain (Met 1-Arg 200) was fused with the C-terminal polyhistidine-tagged Fc region of human IgG1 at the C-terminus.
Accession#
Expressed Host
HEK293 Cells
Species
Human
Predicted N Terminal
Ser 22
Molecule Mass
The recombinant human TIMD3/Fc is a disulfide-linked homodimer after removal of the signal peptide. The reduced monomer consists of 426 amino acids and has a predicted molecular mass of 47.7 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rhTIMD3/Fc monomer is approximately 66 kDa due to glycosylation.
Formulation
Lyophilized from sterile PBS, pH 7.4
1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
2. Please contact us for any concerns or special requirements.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -70℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

TIM-3 Protein, Human, Recombinant (His & Fc Tag): Images

TIM-3 Protein, Human, Recombinant (His & Fc Tag): Alternative Names

CD366 Protein, Human; HAVcr-2 Protein, Human; HAVCR2 Protein, Human; KIM-3 Protein, Human; Tim-3 Protein, Human; TIM3 Protein, Human; TIMD-3 Protein, Human; TIMD3 Protein, Human

TIM-3 Background Information

Hepatitis A virus cellular receptor 2 (HAVCR2), formerly known as T cell immunoglobulin and mucin domain-3 (TIM-3), is a transmembrane glycoprotein expressed on the surface of terminally differentiated Th1 cells but not on Th2 cells. It was the first surface molecule that specifically identifies Th1 cells in both mice and human. Recently, identification of Galectin-9 as a ligand for TIM-3 has established the TIM-3-Galectin-9 pathway as an important regulator of Th1 immunity and tolerance induction. Engagement of Tim-3 by its ligand galectin-9 negatively regulates IFN-gamma secretion and influences the ability to induce T cell tolerance in both mice and man. It suggests a novel paradigm in which dysregulation of the TIM-3-galectin-9 pathway could underlie chronic autoimmune disease states, such as multiple sclerosis. Recent work has explored the role of TIM-3 in systemic lupus erythematosus (SLE), and their results indicate that TIM-3 may represent a novel target for the treatment of SLE. Numerous studies have demonstrated that Tim-3 influences autoimmune diseases, including diabetes and multiple sclerosis, and its role in other inflammatory diseases including allergies and cancer is beginning to become clear. In tumor rejection model, soluble form of Tim-3 (sTim-3) significantly impaired T cell antitumor immunity, evidenced by decreased antitumor CTL activity and reduced amount of tumor-infiltrating lymphocytes in tumor. sTim-3 as an immunoregulatory molecule that may be involved in the negative regulation of T cell-mediated immune response.
Full Name
hepatitis A virus cellular receptor 2
References
  • Geng H, et al. (2006) Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated immune response. J Immunol. 176(3): 1411-20.
  • Anderson AC, et al. (2006) TIM-3 in autoimmunity. Curr Opin Immunol. 18(6): 665-9.
  • Anderson DE. (2007) TIM-3 as a therapeutic target in human inflammatory diseases. Expert Opin Ther Targets. 11(8): 1005-9.
  • Pan HF, et al. (2010) TIM-3 as a new therapeutic target in systemic lupus erythematosus. Mol Biol Rep. 37(1): 395-8.
  • Development of an AlphaLISA Assay for Screening Inhibitors of the TIM-3/Gal-9 Interaction
    Author
    Cao, H;Carlstrom, J;Hopkinton, MA;
    Year
    2017
    Journal
    APPLICATION NOTE
    Application
    AlphaLISA Assays
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait